Unmet Needs in the HFmrEF and HFpEF Landscape

Author(s):

Key Takeaways

Novel therapies for HFmrEF and HFpEF aim to improve symptom management and patient outcomes, addressing current treatment limitations.
Emerging treatments could reduce hospitalization rates and enhance quality of life for patients with HFmrEF and HFpEF.
Personalized treatment options may become available, targeting diverse pathophysiological mechanisms in HFmrEF and HFpEF.

Javed Butler, MD, MPH, MBA, discusses the DAPA ECHO trial data presented at European Society of Cardiology Congress 2024, examining the effects of dapagliflozin on myocardial performance in patients with nondiabetic heart failure, including the study’s objective, design, methodology, results, and key clinical implications for the use of dapagliflozin in this population.

EP: 1.Overview of FINEARTS-HF Trial

EP: 2.Role of MRAs in HFmrEF and HFpEF

EP: 3.Overview of BB Use and Outcomes in HFmrEF and HFpEF

EP: 4.Multi-Modal Treatment Strategy for HFmrEF and HFpEF

Now Viewing

EP: 5.Unmet Needs in the HFmrEF and HFpEF Landscape

EP: 6.Overview of DAPA ECHO Trial

Video content above is prompted by the following:

Based on the new data from the 3 abstracts, what unmet needs could the therapies address within the heart failure (HF) with midrange ejection fraction (EF) and HF with preserved EF landscape?